Idiopathic Intracranial Hypertension (IIH) is a neurological disorder characterised by increased pressure within the skull without an identifiable cause. This condition can lead to symptoms such as headaches, visual disturbances, and papilledema, which is swelling of the optic nerve head.
About the Clinical Trial
A Phase IV, randomised, double-blind, placebo-controlled clinical trial is currently recruiting participants to investigate the impact of tirzepatide on intracranial pressure (ICP) in individuals diagnosed with IIH. The study is conducted at a single centre by Duke University in collaboration with Eli Lilly and Company.
The trial aims to enrol approximately 60 participants aged between 18 and 60 years with a body mass index (BMI) of 30 kg/m2 or higher. Participants will be randomly assigned in a 1:1 ratio to receive either tirzepatide or a placebo over a 12-month period, with doses escalating gradually according to a defined schedule.
Study Design and Outcomes
The primary outcome measure is the change in intracranial pressure assessed through lumbar puncture. Secondary outcomes include changes in retinal nerve fibre layer thickness measured by optical coherence tomography, alterations in papilledema grade via fundus photography, and visual field changes evaluated by perimetric mean deviation.
Statistical analysis will employ analysis of covariance (ANCOVA) to compare changes between the treatment and placebo groups, adjusting for baseline ICP values. The study is designed to maintain quadruple masking, ensuring that participants, care providers, investigators, and outcome assessors remain unaware of group assignments to reduce bias.
Eligibility and Exclusions
Eligible participants must exhibit clinical signs of raised intracranial pressure without secondary causes, be alert and able to consent, and meet specific ophthalmological and neurological criteria. Exclusion criteria include previous bariatric surgery, use of other GLP-1 agonists or anti-obesity medications, certain medical histories such as pancreatitis or thyroid cancer risk, pregnancy, and other conditions that may confound results.
Context and Considerations
This trial represents an important step in exploring the potential role of tirzepatide, a drug primarily studied for metabolic conditions, in managing intracranial pressure related to IIH. It is essential to note that findings from this study are pending, and no clinical recommendations or treatment claims can be made at this stage.
For those interested in the broader field of peptides and their applications in research and wellness, Svelta Labs offers educational resources and products designed to support scientific literacy. Visit Svelta Labs for more information.
Research-use disclaimer: This article is based on clinical trial information and is intended for educational purposes only. It does not provide medical advice, prescribing guidance, or treatment recommendations.
Explore more at sveltalabs.com. Join community.sveltalabs.com.